[MUC16: The Novel Target for Tumor Therapy].

Mucin16 (MUC16), also known as carbohydrate antigen 125 (CA125), is a glycoprotein antigen that can be recognized by the monoclonal antibody OC125 detected from epithelial ovarian carcinoma antigen by Bast et al in 1981. CA125 is not present in normal ovarian tissue but is usually elevated in the serum of epithelial ovarian carcinoma patients. CA125 is the most commonly used serologic biomarker for the diagnosis and recurrence monitoring of epithelial ovarian carcinoma. MUC16 is highly expressed in varieties of tumors. MUC16 can interact with galectin-1/3, mesothelin, sialic acid-binding immunoglobulin-type lectins-9 (Siglec-9), and other ligands. MUC16 plays an important role in tumor genesis, proliferation, migration, invasion, and tumor immunity through various signaling pathways. Besides, therapies targeting MUC16 have some significant achievements. Related preclinical studies and clinical trials are in progress. MUC16 may be a potential novel target for tumor therapy. This article will review the mechanism of MUC16 in tumor genesis and progression, and focus on the research actuality of MUC16 in tumor therapy. This article also provides references for subsequent tumor therapy studies targeting MUC16. .【中文题目：MUC16：肿瘤治疗新靶点】 【中文摘要：黏蛋白16（mucin16, MUC16），又称癌抗原125（carbohydrate antigen 125, CA125），是1981年美国科学家Bast等从卵巢上皮癌抗原中检测出且能被单克隆抗体OC125识别的一种糖蛋白抗原。CA125在正常卵巢组织中不存在，但在卵巢上皮癌患者的血清中常见升高。CA125是卵巢上皮癌诊断和监测复发最常用的血清学生物标志物。MUC16在多种肿瘤中高表达，可以与半乳糖凝集素-1/3（galectin-1/3）、间皮素、唾液酸结合的免疫球蛋白样凝集素-9（sialic acid-binding immunoglobulin-type lectins-9, Siglec-9）等配体结合，通过多种肿瘤相关信号通路，对肿瘤发生发展、迁移侵袭及肿瘤免疫具有重要作用。靶向MUC16的治疗方式已经取得一定成效，相关临床前研究以及临床试验正在进行当中，MUC16可能是一个有潜力的肿瘤治疗新靶点。本文重点阐述MUC16在肿瘤发生发展中的作用，关注其在肿瘤治疗中的研究现状，为后续靶向MUC16的肿瘤治疗研究提供参考。 】 【中文关键词：MUC16；肿瘤治疗；粘蛋白；免疫治疗；靶向治疗】.